Developmental funds are requested to recruit faculty level scientists in areas of strategic need, to support pilot projects that allow Fox Chase Cancer Center scientists to pursue innovative ideas in high priority research areas, and to support technology and methodology development projects related to the Center's discovery mission and strategic objectives. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer reviewed funding within 24 months of their appointment Of that amount $5.1 million was garnered by investigators directly leveraging developmental funds. Also, this class competed successfully for a further $1.6 million in competitive foundation support. During the last CCSG cycle, pilot project funds were utilized in the second, fifth and sixth years to support potential high-impact projects, largely from established investigators. The 12 funded projects have already produced two funded grants and seven publications. During the past CCSG cycle, the Center provided start up support for a High Throughput Screening Facility that has become one of the 16 established shared facilities. In the present CCSG application we seek partial support for the 25 new investigators identified as necessary to address the critical mass needs of the Center's five existing programs over the next CCSG cycle. This request represents less than 25% of the average cost of supporting a new investigator. We also seek support for partial funding for four translational pilot projects per year. These CCSG funds will be matched by institutional funds. Finally, we seek partial funding for technology developments and informatics initiatives in support of the Center's Institute for Personalized Medicine. All of these developmental funds are considered vital to achieving the discovery objectives outlined in the Center's Strategic Plan.

Public Health Relevance

Development funds are critical for use in recruiting faculty level scientists and to support pilot projects at Fox Chase Cancer Center allowing scientists to pursue innovative ideas in high priority research areas. These funds are also necessary to promote emerging technologies used in cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475331
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$275,462
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Boland, Patrick M; Meyer, Joshua E; Berger, Adam C et al. (2016) Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol :
Heckman, Carolyn J; Handorf, Elizabeth A; Darlow, Susan D et al. (2016) An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychol :
Meropol, Neal J; Wong, Yu-Ning; Albrecht, Terrance et al. (2016) Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol 34:469-78
Hayakawa, K; Formica, A M; Colombo, M J et al. (2016) Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. Leukemia 30:1510-9
Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50
Duong-Ly, Krisna C; Devarajan, Karthik; Liang, Shuguang et al. (2016) Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep 14:772-81
Meeker, Caitlin R; Geynisman, Daniel M; Egleston, Brian L et al. (2016) Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract 12:e755-64
Geynisman, Daniel M; Handorf, Elizabeth; Wong, Yu-Ning et al. (2016) Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med 5:192-9
Kurimchak, Alison M; Shelton, Claude; Duncan, Kelly E et al. (2016) Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-86
Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35

Showing the most recent 10 out of 884 publications